Zevra Therapeutics, Inc. Business Acquisition, Pro Forma Revenue
Zevra Therapeutics, Inc. (ZVRA) reported Business Acquisition, Pro Forma Revenue of $8.47 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2024-11-13
- Zevra Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2024-06-30 was $8.47M.
- Zevra Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2024-03-31 was $3.18M.
- Zevra Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2023-12-31 was $12.79M.
- Zevra Therapeutics, Inc. business acquisition, pro forma revenue for the quarter ending 2023-09-30 was $3.27M.
- Zevra Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2023 was $27.70M, a 164.92% increase from fiscal 2022.
- Zevra Therapeutics, Inc. business acquisition, pro forma revenue for fiscal 2022 was $10.46M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2024-06-30 | $8.47M 10-Q · filed 2024-08-14 | $11.65M 10-Q · filed 2024-08-14 | $24.44M derived: sum of 3 quarters · filed 2024-08-14 | $27.70M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $3.18M 10-Q · filed 2024-05-09 | $15.97M derived: sum of 2 quarters · filed 2024-05-09 | $19.23M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-12-31 | $12.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $16.06M derived: sum of 2 quarters · filed 2024-11-13 | $27.70M 10-K · filed 2024-04-01 | |
| 2023-09-30 | $3.27M 10-Q · filed 2024-11-13 | $14.91M 10-Q · filed 2024-11-13 | ||
| 2022-12-31 | $10.46M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |